Efficacy and Satisfaction of Cyclosporine 0.1% in Patients with Vernal Keratoconjunctivitis

Vernal keratoconjunctivitis (VKC) is a severe form of ocular allergy that compromises the quality of life of affected patients. Topical cyclosporine 0.1% cationic emulsion (CsA-CE) has been recently authorized for the treatment of severe VKC. We treated 29 VKC patients with on-label CsA-CE and recorded signs and symptoms, subjective patient’s treatment satisfaction and the additional use of topical corticosteroids in case of exacerbations. CsA-CE was effective in reducing signs and symptoms in daily clinical practice. The overall subjective improvement of symptoms, efficacy of the treatment, tolerability to the drug and compliance reached a high level of subjective satisfaction score.55% of treated patients required the additional use of a 3-day course of topical dexamethasone with 1.13 ± 0.81 mean courses/month. In conclusions, VKC patients reported an overall high satisfaction with used the on-label topical CsA-CE with a limited use of additional topical corticosteroid treatment.

春季角结膜炎（Vernal keratoconjunctivitis, VKC）是一种严重的眼部过敏性疾病，可显著降低受累患者的生活质量。近期，0.1%环孢素阳离子乳剂（CsA-CE）获批用于重度VKC的治疗。本研究对29例VKC患者采用符合药品说明书适应症的CsA-CE进行治疗，记录了患者的体征与症状、主观治疗满意度，以及病情急性发作时额外使用局部糖皮质激素的情况。结果显示，CsA-CE在日常临床实践中可有效缓解患者的体征与症状；患者在症状整体主观改善、治疗有效性、药物耐受性及治疗依从性方面的主观满意度评分均处于较高水平。55%的受试患者需额外接受为期3天的局部地塞米松治疗，平均每月治疗疗程为1.13±0.81次。综上所述，采用符合说明书适应症的局部CsA-CE治疗的VKC患者整体满意度较高，且额外局部糖皮质激素的使用频次有限。